Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
90 results
  • Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis. [Journal Article]
    J Dermatol 2019Ono R, Yagi M, … Purohit VS
  • Crisaborole ointment, 2%, is a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis (AD). This parallel-cohort, phase 1 study was conducted to investigate skin irritation potential and safety of crisaborole in healthy Japanese adults (cohort 1) and the safety and pharmacokinetic profile of crisaborole and metabolites AN7602 and AN8323 in Japanese adu…
  • Soft drugs for dermatological applications: recent trends. [Review]
    Drug Discov Today 2019; 24(12):2234-2246Aprile S, Serafini M, Pirali T
  • A soft drug (SD) displays a metabolically labile spot and, after having exerted its activity in the site of action, undergoes a fast metabolism, leading to inactive metabolites. The SD approach has recently found widespread application in the dermatological field because it provides a means of localising the therapeutic effect in skin, while minimising systemic exposure. The literature is rapidly…
  • Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. [Review]
    J Allergy Clin Immunol Pract 2019Fishbein AB, Silverberg JI, … Ong PY
  • Atopic dermatitis (AD) is one of the most common inflammatory skin diseases affecting children and adults. The intense pruritus and rash can be debilitating, significantly impairing quality of life. Until recently, treatment was largely nonspecific and, in severe disease, sometimes ineffective and/or fraught with many side effects. Now, multiple agents targeting specific disease pathways are avai…
  • New and Emerging Therapies for Pediatric Atopic Dermatitis. [Journal Article]
    Paediatr Drugs 2019; 21(4):239-260Nguyen HL, Anderson KR, Tollefson MM
  • Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by pruritus, inflammatory erythematous skin lesions, and skin-barrier defect. Current mainstay treatments of emollients, steroids, calcineurin inhibitors, and immunosuppressants have limited efficacy and potentially serious side effects. Recent advances and understanding of the pathogenesis of AD have resulted in new the…
  • Boron in drug design: Recent advances in the development of new therapeutic agents. [Review]
    Eur J Med Chem 2019; 179:791-804Fernandes GFS, Denny WA, Dos Santos JL
  • Advances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade®), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After it…
New Search Next